BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 23519302)

  • 1. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines.
    Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Raine-Bennett T; Gage JC; Kinney WK
    J Low Genit Tract Dis; 2013 Apr; 17(5 Suppl 1):S28-35. PubMed ID: 23519302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The low risk of precancer after a screening result of human papillomavirus-negative/atypical squamous cells of undetermined significance papanicolaou and implications for clinical management.
    Gage JC; Katki HA; Schiffman M; Castle PE; Fetterman B; Poitras NE; Lorey T; Cheung LC; Behrens C; Sharma A; Zhao FH; Cuzick J; Yang ZH; Kinney WK
    Cancer Cytopathol; 2014 Nov; 122(11):842-50. PubMed ID: 25045058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Similar Risk Patterns After Cervical Screening in Two Large U.S. Populations: Implications for Clinical Guidelines.
    Gage JC; Hunt WC; Schiffman M; Katki HA; Cheung LA; Myers O; Cuzick J; Wentzensen N; Kinney W; Castle PE; Wheeler CM;
    Obstet Gynecol; 2016 Dec; 128(6):1248-1257. PubMed ID: 27824767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Invader human papillomavirus (HPV) type 16 and 18 assays as adjuncts to HPV screening of cervical papanicolaou smears with atypical squamous cells of undetermined significance.
    Wong AK; Chan RC; Nichols WS; Bose S
    Cancer; 2009 Feb; 115(4):823-32. PubMed ID: 19127558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinician's view: role of human papillomavirus testing in the American Society for Colposcopy and Cervical Pathology Guidelines for the management of abnormal cervical cytology and cervical cancer precursors.
    Cox JT;
    Arch Pathol Lab Med; 2003 Aug; 127(8):950-8. PubMed ID: 12952506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.
    Kulasingam SL; Hughes JP; Kiviat NB; Mao C; Weiss NS; Kuypers JM; Koutsky LA
    JAMA; 2002 Oct; 288(14):1749-57. PubMed ID: 12365959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
    Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
    Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis.
    Sherman ME; Lorincz AT; Scott DR; Wacholder S; Castle PE; Glass AG; Mielzynska-Lohnas I; Rush BB; Schiffman M
    J Natl Cancer Inst; 2003 Jan; 95(1):46-52. PubMed ID: 12509400
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of precancer and follow-up management strategies for women with human papillomavirus-negative atypical squamous cells of undetermined significance.
    Safaeian M; Solomon D; Wacholder S; Schiffman M; Castle P
    Obstet Gynecol; 2007 Jun; 109(6):1325-31. PubMed ID: 17540804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of high-risk human papillomavirus DNA testing to deal with atypical squamous cells undetermined significance and low squamous intraepithelial lesion].
    Guo YL; You K; Geng L; Zhang XW; Shen XY; Yao YJ; Fan XH
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 38(5):480-2. PubMed ID: 17068618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Switch from cytology-based to human papillomavirus test-based cervical screening: implications for colposcopy.
    Porras C; Wentzensen N; Rodríguez AC; Morales J; Burk RD; Alfaro M; Hutchinson M; Herrero R; Hildesheim A; Sherman ME; Wacholder S; Solomon D; Schiffman M
    Int J Cancer; 2012 Apr; 130(8):1879-87. PubMed ID: 21607948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HPV Cotesting of Unsatisfactory Papanicolaou Tests: Implications for Follow-up Intervals.
    Chen F; Hsu Lin L; Hindi I; Sun W; Shafizadeh N; Szeto O; Brandler TC; Simsir A
    Am J Clin Pathol; 2023 Aug; 160(2):137-143. PubMed ID: 37052613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Follow-up findings for women with human papillomavirus-positive and atypical squamous cells of undetermined significance screening test results in a large women's hospital practice.
    Armah H; Austin RM; Dabbs D; Zhao C
    Arch Pathol Lab Med; 2009 Sep; 133(9):1426-30. PubMed ID: 19722749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice.
    Katki HA; Kinney WK; Fetterman B; Lorey T; Poitras NE; Cheung L; Demuth F; Schiffman M; Wacholder S; Castle PE
    Lancet Oncol; 2011 Jul; 12(7):663-72. PubMed ID: 21684207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test.
    Castle PE; Fetterman B; Poitras N; Lorey T; Shaber R; Schiffman M; Demuth F; Kinney W
    Obstet Gynecol; 2011 Mar; 117(3):650-656. PubMed ID: 21343769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk-adapted primary HPV cervical cancer screening project in Wolfsburg, Germany--experience over 3 years.
    Luyten A; Scherbring S; Reinecke-Lüthge A; Braun BE; Pietralla M; Theiler K; Petry KU
    J Clin Virol; 2009 Nov; 46 Suppl 3():S5-10. PubMed ID: 20129072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human papillomavirus testing in primary cervical screening and abnormal Papanicolaou management.
    Cox JT
    Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S15-25. PubMed ID: 16729900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.